BioSpace

Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial

Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.

By BioSpace

1 min read
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights